Metastatic Cancer and Liver Cancer Clinical Trial Using yttrium Y 90 glass microspheres and capecitabine

- The folks at Northwestern University are studying the effects of capecitabine; yttrium Y 90 glass microspheres on Metastatic Cancer and Liver Cancer in individuals ages 18 years and older. This clinical trial is slated to start March 2009 and is expected to end circa December 2015.

312-695-4440
Mary Mulcahy, MD
Overall Study Contact Info
StatusName Contact Phone
RecruitingMary Mulcahy, MDm-mulcahy@northwestern.edu312-695-4440

This study is officially titled, "Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver."

Locations

Northwestern University

Chicago, Illinois - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.